(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Edgewise Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast EWTX's revenue for 2026 to be $3,046,569,056, with the lowest EWTX revenue forecast at $3,046,569,056, and the highest EWTX revenue forecast at $3,046,569,056. On average, 4 Wall Street analysts forecast EWTX's revenue for 2027 to be $5,875,308,424, with the lowest EWTX revenue forecast at $4,195,696,822, and the highest EWTX revenue forecast at $10,080,335,364.
In 2028, EWTX is forecast to generate $20,631,556,058 in revenue, with the lowest revenue forecast at $8,756,981,930 and the highest revenue forecast at $31,716,687,979.